Benzinga | Jun 1, 2021 08:06AM EDT

Enlivex Announces Issuance of New Canadian Patent Covering Pharmaceutical Compositions, Manufacturing Methods and Uses Of Allocetra Immunotherapy

Enlivex Therapeutics Ltd., (NASDAQ:ENLV, the &quot, Company&quot, ))))), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced that the Canadian Intellectual Property Office has issued Canadian Patent No. 2,893,962 covering AllocetraTM, the Company's immunotherapy product candidate. The new patent is expected to provide added intellectual property protection for pharmaceutical compositions, manufacturing methods and uses of AllocetraTM.

Oren Hershkovitz, PhD, CEO of Enlivex, stated, "We are pleased to have this patent granted in Canada, which adds to existing AllocetraTM patents in various countries around the world. We currently continue to focus our clinical development efforts on life-threatening diseases with high mortality rates and no effective treatments such as sepsis, COVID-19, and solid tumors."

AllocetraTM is being developed as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as "unmet medical needs", as a stand-alone therapy or in combination with leading therapeutic agents.